BCR and posterior cortical atrophy: BCR alone should not warrant an immediate change in treatment. PSADT should be estimated if BCR occurs and should be determined from at least three measurements over a 6-month period. Enrollment in ongoing clinical trials should be considered. Routine administration of ADT should not be offered to individuals with PCa solely based on BCR, unless they meet certain criteria:Symptomatic local disease progressionPresence of proven metastasesPSADT of less than three months